| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Granzyme B (G,H);3.4.21.79;CTLA-1;Cytotoxic cell protease 1;CCP1;Fragmentin-2;Gzmb;Ctla-1, Ctla1; |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Expression System | |
| Gene ID | |
| Immunogen | Expression system for standard: NS0; Immunogen sequence: I21-S247 |
| Product Type | |
| Reactivity | |
| Sample Type(s) | cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA). |
| Sensitivity | |
| Storage | |
| Target | |
| UniProt # |
Background
Also known as: Granzyme B (G, H), 3.4.21.79, CTLA-1, Cytotoxic cell protease 1, CCP1, Fragmentin-2, Gzmb.
Mouse Granzyme B (Gzmb) is an established target in many assay panels, supporting hypothesis testing across diverse biological systems. This target is frequently investigated in Molecular & Cellular Biology research contexts. Proteases and extracellular matrix (ECM) components are central to tissue architecture and remodeling. In many experimental contexts, changes in ECM-related proteins reflect shifts in cell adhesion, migration, barrier integrity, or matrix turnover.
Biological function and remodeling context
Matrix remodeling is influenced by the balance between synthesis and degradation, often regulated by inflammatory cues, mechanical stress, and growth-factor signaling. Protease activity can unmask or release bioactive fragments, while altered ECM composition can feed back on cell behavior through mechanotransduction and receptor engagement.
Why it matters in research
- Remodeling readout: Quantification can support studies of fibrosis, wound repair, and invasion models.
- Microenvironment state: Levels may reflect stromal activation, barrier disruption, or matrix turnover.
- Mechanistic linkage: Pairing with inflammatory and growth-factor markers can clarify drivers of remodeling.
Disease and translational relevance
ECM remodeling and protease regulation are frequently discussed in the literature across oncology, cardiovascular, pulmonary, and inflammatory disease models. Interpretation of abundance should consider whether the measured analyte represents pro-forms, active forms, or fragments, and whether binding partners in the matrix influence detectability.
Sample data
| Concentration (pg/ml) | 0 | 15.6 | 31.2 | 62.5 | 125 | 250 | 500 | 1000 |
| O.D. | 0.03 | 0.077 | 0.119 | 0.218 | 0.374 | 0.694 | 1.339 | 2.122 |
Intra/inter assay consistency
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 16 | 16 | 16 | 24 | 24 | 24 |
| Mean (pg/ml) | 31 | 151 | 486 | 31 | 149 | 483 |
| Standard deviation | 1.39 | 11.77 | 25.75 | 1.89 | 14 | 29.94 |
| CV (%) | 4.5% | 7.8% | 5.3% | 6.1% | 9.4% | 6.2% |
Kit components
Description|Quantity Pre-coated 96-well strip microplate|1 Standard|2 vials Biotinylated antibody (100x)|100ul Avidin-Biotin-Peroxidase Complex (100x)|100ul Sample Diluent|30ml Antibody Diluent|12ml Avidin-Biotin-Peroxidase Diluent|12ml Color Developing Reagent (TMB)|10ml Stop Solution|10ml Wash Buffer (25x)|20ml Adhesive plate sealers|4Materials required but not provided
- Microplate Reader capable of reading absorbance at 450nm.
- Incubator.
- Automated plate washer (optional).
- Pipettes and pipette tips capable of precisely dispensing 0.5 µl through 1 ml volumes of aqueous solutions.
- Multichannel pipettes are recommended for large amount of samples.
- Deionized or distilled water.
- 500ml graduated cylinders.
- Test tubes for dilution.
►How many samples can I run per plate?
►What sample dilution should I use?
►Why is my signal weak or absent?
►Why is my background signal high?
►Are the kit components sterile?
►How do I analyze my ELISA results?
►How should I store samples before running the assay?
►What positive and negative controls should I include?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Ma et al. (2025). Multiplex Methionine Modulating Hydrogel for Cancer Metabolic Therapy. ADVANCED MATERIALS.
- Zhang et al. (2025). NIR-triggered programmable nanomotor with H2S and NO generation for cascading oncotherapy by three-pronged reinforcing I…. Materials Today Bio.
- Long et al. (2024). Unzippable Siamese Nanoparticles for Programmed Two-Stage Cancer Immunotherapy. ADVANCED MATERIALS.
- QiuLiman et al. (2024). TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. EMBO Molecular Medicine.
- Liang et al. (2024). Dismantlable Coronated Nanoparticles for Coupling the Induction and Perception of Immunogenic Cell Death. ADVANCED MATERIALS.
- Li et al. (2024). Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota. Food & Function.
- Baoyuan et al. (2024). Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize the…. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.
- Qiuyu et al. (2023). Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an i…. Communications Biology.
- Guo et al. (2023). Targeted Reprogramming of Vitamin B3 Metabolism as a Nanotherapeutic Strategy towards Chemoresistant Cancers. ADVANCED MATERIALS.
- Xu et al. (2023). Slimming and Reinvigorating Tumor-Associated Dendritic Cells with Hierarchical Lipid Rewiring Nanoparticles. ADVANCED MATERIALS.
- Jie et al. (2022). EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nature Communications.
- Cao et al. (2022). Nanoplatform Self-Assembly from Small Molecules of Porphyrin Derivatives for NIR-II Fluorescence Imaging Guided Photothe…. Advanced Healthcare Materials.
- Zheng et al. (2022). CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint block…. Molecular Therapy-Nucleic Acids.
- Yubo et al. (2025). Dual asparagine-depriving nanoparticles against solid tumors. Nature Communications.